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Human immunodeficiency virus (HIV)-1 has infected >75 million individuals globally,
and, according to the UN, is responsible for ∼2.1 million new infections and 1.1
million deaths each year. Currently, there are ∼37 million individuals with HIV infection
and the epidemic has already resulted in 35 million deaths. Despite the advances of
anti-retroviral therapy (ART), a cost-effective vaccine remains the best long-term solution
to end the HIV-1 epidemic especially given that the vast majority of infected individuals
live in poor socio-economic regions of the world such as Sub-Saharan Africa which
limits their accessibility to ART. The modest efficacy of the RV144 Thai trial provides
hope that a vaccine for HIV-1 is possible, but as markers for sterilizing immunity are
unknown, the design of an effective vaccine is empirical, although broadly cross-reactive
neutralizing antibodies (bNAb) that can neutralize various quasispecies of HIV-1 are
considered crucial. Since HIV-1 transmission often occurs at the genito-rectal mucosa
and is cell-associated, there is a need to develop vaccines that can elicit CD8+ T cell
immunity with the capacity to kill virus infected cells at the genito-rectal mucosa and the
gut. Here we discuss the recent progress made in developing T cell-mediated vaccines
for HIV-1 and emphasize the need to elicit mucosal tissue-resident memory CD8+ T
(CD8+ Trm) cells. CD8+ Trm cells will likely form a robust front-line defense against
HIV-1 and eliminate transmitter/founder virus-infected cells which are responsible for
propagating HIV-1 infections following transmission in vast majority of cases.
Keywords: human immunodeficiency virus, HIV-1, HIV vaccine, mucosal immunity, T cell, tissue resident memory,
CD8+ T cell, vagina
INTRODUCTION
Since the discovery of human immunodeficiency virus (HIV)-1 as the causative agent of the
acquired immunodeficiency syndrome (AIDS), significant progress has been made to thwart the
worldwide spread of the virus despite many setbacks. The “Berlin Patient” highlighted that a cure
for HIV/AIDS is possible through bone marrow transplantation (Hütter et al., 2009). However, the
excessive cost of this procedure and the lack of compatible donors severely limit the application
of this cure strategy. The use of anti-retroviral therapy (ART) remains the most feasible medical
intervention to suppress the virus in patients. Furthermore, early treatment of infected individuals
with ART can prevent HIV-1 transmission to uninfected individuals (Cohen et al., 2011) while the
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daily use of anti-retroviral drugs Truvada (i.e., for pre-exposure
prophylaxis) by individuals can successfully prevent acquisition
of HIV-1 (Molina et al., 2015). Unfortunately, it is estimated that
more than half of the HIV-infected individuals are undiagnosed
and 3/5 people infected with this virus do not have access to ART.
This hinders the ability of ART to control the epidemic and given
that ART does not eliminate latent reservoirs of HIV-1, strict
and life-long adherence of ART is required for the therapy to be
effective in patients.
A vaccine is essential to complement the efforts of ART
to bring an end to HIV/AIDS especially in HIV endemic
regions (e.g., Sub-Saharan Africa) manifested by the inability
of patients to access ART adequately due to their poor socio-
economic status. The main limitations to the development of an
effective HIV-1 vaccine include the ability of the virus to mutate
rapidly to facilitate immune escape and its ability to infect,
deplete and establish viral reservoirs in CD4+ T cells. Despite
these limitations, vaccines that elicit (i) broadly neutralizing
antibodies (bNAb), (ii) non-neutralizing antibodies that direct
virus-infected cells for destruction, or (iii) CD8+ T cell immunity
have emerged as attractive targets for the future of HIV-1 vaccine
development. In this brief review, we will discuss the avenues and
challenges for developing an effective T cell-mediated vaccine for
HIV-1 with a particular focus on CD8+ T cell immunity.
WHY DO WE NEED A VACCINE WHICH
WILL ELICIT CD8+ T CELL IMMUNITY?
There are several reasons which support the development of a
vaccine to elicit CD8+ T cell immunity against HIV-1.
1. Elite controllers of HIV-1 and simian immunodeficiency
virus (SIV) provide valuable clues for vaccine development
because these individuals are able to suppress the virus to
undetectable levels for prolonged periods in the absence of
ART. Although enhanced activity of anti-viral CD8+ T cells
is not always predictive of elite control of infection (Blankson,
2010), numerous studies in humans and macaques suggest
that elite control strongly correlates with- or is dependent on-
anti-viral CD8+ T cell responses that target conserved regions
of SIV and HIV-1 proteins (Pontesilli et al., 1998; Saez-Cirion
et al., 2007; Wijesundara et al., 2011; Chowdhury et al., 2015).
2. Anti-viral CD8+ T cells can directly kill virus-infected cells
and can establish residency at sites where HIV-1 will likely
be encountered during transmission (see below). Given that
most HIV-1 infections are initiated by a single variant (i.e.,
transmitted/founder virus) (Zhu et al., 1993; Keele et al., 2008),
the presence of HIV-specific CD8+ T cells at transmission
sites will likely be crucial for reducing the viral set point and
thereby reducing the reservoir size.
3. Passive transfer studies and vector-based immunoprophylaxis
studies suggest that bNAb will be very effective in protection
against HIV-1 (Balazs et al., 2011; Scheid et al., 2016; Caskey
et al., 2017). Non-neutralizing antibodies and bNAb with the
capacity to direct killing of cell-associated forms of HIV-1 have
also been identified (Haynes et al., 2012; Malbec et al., 2013;
Bruel et al., 2016). Some recent progress has also been made
to develop a vaccine which will elicit bNAb (Pauthner et al.,
2017). However, a significant conceptual breakthrough is still
needed to develop a vaccination strategy to elicit high titres
of potent bNAb and non-neutralizing antibodies especially
at HIV-1 transmission sites. Furthermore, to be effective
in preventing cell-to-cell transmission by eliminating cell-
associated forms of the virus at transmission sites, antibody-
based vaccine strategies will probably require sufficient
numbers of innate effector cells (e.g., natural killer cells) to be
present at transmission sites prior to a transmission event.
4. Therapeutic vaccines against HIV-1 and SIV have failed to
demonstrate efficacy. However, a recent study demonstrated
that a vaccination regimen which elicited broad CD8+ T
cell immunity to SIV Gag, Pol, and envelope (Env) proteins
protected SIV-infected macaques undergoing treatment
interruption (Borducchi et al., 2016). Following on from
this landmark study, a “kick and kill” approach (Shan et al.,
2012) was exploited to increase the therapeutic efficacy
of a recombinant modified vaccinia virus Ankara (MVA)
vaccine in the ongoing BCN02-Romi (NCT02616874) proof
of concept study. The findings presented by Beatriz Mothe
at the 2017 Conference on Retroviruses and Opportunistic
Infections in Seattle suggest that CD8+ T cell responses
targeting conserved regions of HIV-1 were involved in
protection.
THE IMPORTANCE OF MUCOSAL
IMMUNITY FOR HIV-1 VACCINE EFFICACY
HIV-1 is first encountered at the mucosa (genito-rectal tract),
and the gastro-intestinal tract is the major site of HIV replication
and CD4+ T cell depletion (Veazey and Lackner, 1998). It is
well-established that a vaccine delivered mucosally can induce
long-lasting immune responses at these mucosal sites, as systemic
vaccination rarely induces optimal sustained mucosal immunity
(Belyakov and Ahlers, 2009; Fouda et al., 2013; Sun et al., 2013).
Mucosa-associated lymphoid tissues are linked to the “common
mucosal immune system,” whereby antigenic stimulation at
one site results in both local and distant mucosal immunity.
According to the site of mucosal vaccination (i.e., oral, nasal,
rectal, or vaginal), the immunity generated at different sites
can be vastly different, mainly due to the unique antigen
presentation mechanisms (which is dependent on the type of
antigen presenting cells present at different antigen-sampling
sites) and the homing markers they acquire at the local mucosa
(Trivedi and Ranasinghe, 2015; Trivedi et al., 2015). For example,
a vaccine delivered intranasally will induce mucosal immunity
at the lung, genito-rectal tract and also the gastro-intestinal
tract, whereas rectal delivery will only induce immunity in the
rectum and the some instances in the intestine (Ranasinghe et al.,
2011; De Rose et al., 2014; Tomusange et al., 2016a). However,
different adjuvants and cytokines have the capacity to promote
T cell migration to the mucosa by modulating the initial antigen
presenting cell environment at the vaccination site (Xi et al., 2012;
Trivedi et al., 2014). This may explain how some viral vectors
(i.e., pox viral vector-based vaccines) delivered systemically can
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induce mucosal immunity (Stevceva et al., 2002; Marlin et al.,
2017).
Despite that HIV-1 is transmitted mainly through mucosal
surfaces, no mucosal vaccine has yet entered efficacy trials in
humans, although a few phase I trials have been conducted
(Leroux-Roels et al., 2013; Nyombayire et al., 2017). Studies in
non-human primate models have demonstrated that mucosal
CD8+ T cell responses can better control a mucosal viral
challenge while systemic CD8+ T cell immunity is not fully
effective against mucosal infection (Kent et al., 2005; Belyakov
et al., 2006; Ferre et al., 2009). Several studies in animal models
from our laboratories suggest that mucosal vaccination strategies
can enhance the quality, viz. avidity and polyfunctionality, of
HIV-specific CD8+ T cells and protection against surrogate
HIV-1 challenge models (Ranasinghe et al., 2007, 2013, 2014).
High quality CD8+ T cells can recognize and respond to low
densities of peptide-major histocompatibility class I complexes,
thereby eliminating infected cells at very early stages of infection
(Alexander-Miller et al., 1996; Wijesundara and Ranasinghe,
2012). Several studies in humans suggest that high quality CD8+
T cell responses correlate with elite control of HIV-1 infection
(Betts et al., 2006; Almeida et al., 2007; Berger et al., 2011).
Consequently mucosal vaccination strategies are desirable to
achieve protective outcomes against HIV-1 infections especially
given that mucosal immunisations can elicit high quality mucosal
CD8+ T cell responses. It is also likely that a mucosal vaccination
regimen could be exploited to elicit tissue resident memory
CD8+ T cells in the genito-rectal mucosa, which will likely form
a front-line defense against HIV-1 as discussed below.
IMPLICATIONS FOR ELICITING TISSUE
RESIDENT MEMORY CD8+ T CELLS
The optimum protective outcomes following vaccination are
achieved if immunity is established at sites where pathogens
are initially encountered or migrate to in order to establish
persistence or cause disease. Several recent discoveries in mice
suggest that the presence of CD8+ tissue resident memory T
(Trm) cells significantly enhance or are obligatory for protection
against infections resulting from influenza virus, herpes simplex
virus (HSV), vaccinia virus (VV), and Plasmodium berghei
exposure (Fernandez-Ruiz et al., 2016; Mueller and Mackay,
2016). CD8+ Trm cells reside in tissues for the lifespan of the
individual and the expression of CD69, CD103 (Mueller and
Mackay, 2016), and/or high expression of CD11a (McNamara
et al., 2017) are unique biomarkers that can be used to identify
these cells in tissues of mice.
The vast majority of HIV-1 transmissions occur through
sexual intercourse and heterosexual intercourse accounts for
an estimated 70–80% of global HIV-1 transmissions. Thus, the
appearance of HIV-specific CD8+ Trm cells in the rectal or
cervicovaginal mucosa will likely contribute to protection during
initial exposure to HIV-1 resulting from sexual transmission
(Figure 1). The first study to describe the use of a vaccination
regimen to elicit vaginal CD8+ Trm cells used a “prime and
pull” strategy against HSV-2 (Shin and Iwasaki, 2012). The
strategy involved priming the CD8+ T cells with a replication
defective HSV-2 subcutaneously and then “pulling” the primed
cells into the vaginal mucosa following intravaginal (i.vag) topical
application of the CXCL9 and CXCL10. A few studies since
have used i.vag delivery of human papillomavirus pseudovirions
(HPV PsV) to induce the formation of cervicovaginal CD8+
Trm cells which correlated with protection against intravaginal
challenge with VV and HSV (Çuburu et al., 2012, 2015). The
cervicovaginal CD8+ Trm cells that were established following
i.vag immunisations with HPV PsV express CD44, CD69,
CXCR3, CD49a (α1 integrin), and CD103 (Çuburu et al., 2015).
These studies provide promise that vaccines can be exploited
to elicit CD8+ Trm cells in the genito-rectal mucosa for
protection against HIV-1 but several challenges remain in order
to achieve this goal. Ideally, an HIV-1 vaccine will not require
i.vag delivery as studies in macaques have highlighted that it
will be difficult for vaccine vectors to penetrate the epithelium
barrier of the vagina (Xu et al., 2013). Even in mice, i.vag delivery
of HPV PsV required the use of progestins (Depo-Provera) to
reduce the thickness of the vaginal epithelium and ensure PsV
infection of cervicovaginal keratinocytes. Although a few recent
studies suggest that expression of CD69 and CD103 could be used
to characterize CD8+ Trm cells in the vagina of humans (Moylan
et al., 2016; Posavad et al., 2017), the markers that uniquely
represent these cells in the genito-rectal mucosa in macaques and
humans are poorly characterized or unclear.
CD4+ T cell help allows dendritic cells to effectively prime
effector CD8+ T cell responses and facilitate entry of effector
CD8+ T cells into the female reproductive tract and ensure
long-term survival of memory CD8+ T cells (Laidlaw et al.,
2016). It is likely that a vaccine will need to elicit CD4+ T
cell helper responses for efficient induction and survival of
CD8+ Trm cells in cervicovaginal tissues. However, CD4+ T
cells are major targets of HIV-1 infection and provision of
cytokines such as interleukin-15 and type I interferons can be
used to overcome the requirement of CD4+ T cell help for
priming and survival of CD8+ T cells (Laidlaw et al., 2016). The
presence/contribution of vaginal CD4+ Trm cells in protection
against- or pathogenesis of- HIV infection is not well-understood
(Figure 1). A better understanding of the requirement of CD4+
T helper cell responses for eliciting long-term CD8+ Trm cell
responses in the reproductive tract and the rectum is necessary
for rational HIV-1 vaccine design.
VECTORS AND IMMUNOGENS: LESSONS
FROM HUMANS AND MACAQUES
The failures of the only phase IIb/phase III trials (STEP, HVTN
503, and HVTN 505) to test the efficacy of a vaccine designed to
elicit CD8+ T cells (Buchbinder et al., 2008; Hammer et al., 2013)
have highlighted that the choice of vectors and immunogens
are important determinants of vaccine efficacy in humans. In
summary, the outcomes of these trials suggest that irrespective
of the circumcision status of vaccine recipients and the presence
of pre-existing immunity to Adenovirus serotype 5 (Ad5), the
Ad5 vector used for vaccination is ineffective in humans. The
exact reasons for the lack of efficacy in these trials is not known.
However, eminent researchers have predicted that this could be
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FIGURE 1 | The importance of cervicovaginal Trm cells in protection against
HIV-1. Cervicovaginal Trm cells will migrate through the cervicovaginal tissues
for the lifespan of an individual and do not need to be recruited to the cervix or
the vagina unlike other memory T cell subsets (which could take days to be
recruited to these sites following primary exposure) during HIV-1 exposure.
Thus, the presence of CD8+ Trm cells in cervicovaginal tissues is crucial to kill
transmitted cell-associated forms of HIV and nascent infected cells resulting
from cell-free virus during transmission. Most importantly, the
transmitter/founder virus which initiates the HIV infection will likely be most
vulnerable for destruction when CD8+ Trm cells are present at the
cervicovaginal mucosa during primary exposure. Consequently, the likelihood
of the virus spreading systemically, especially to the gut where a vast majority
of CD4+ T cells are depleted during acute infection, is minimized or prevented.
Furthermore, the presence of these Trm cells in this instance is also expected
to significantly reduce the viral set point to an extent that it is unlikely for the
infected individual to transmit the virus. It is unclear whether CD4+ Trm cells
form in the cervicovaginal mucosa, whether they can act as targets for HIV
infection or whether they will provide essential help to CD8+ Trm cells. The
protective role of CD8+ Trm cells will likely apply to scenarios where HIV-1 is
exposed in the rectum although there are no studies to demonstrate how
these cells can be elicited in this site.
due to the presence of Ad5-specific CD4+ T cells at mucosal sites
(Barouch, 2010) and immunodominant CD8+ T cell responses
directed to the highly variable Env protein (McMichael and Koff,
2014).
After the failures of the Ad5 vaccine, cytomegalovirus
(CMV), Adenovirus serotype 26 (Ad26), Adenovirus serotype 35
(Ad35), and MVA vectors have emerged as extremely promising
candidates for eliciting protective T cell responses against HIV-
1. Vaccination of macaques with rhesus CMV encoding SIV
Gag, Pol, Env, Rev, Nef, and Tat proteins provided superior and
long-term control of SIVmac251 infection in 5/12 intra-rectally
challenged animals (Hansen et al., 2011). Protection in this
study was associated with robust effector memory CD8+ T cell
responses and CD8+ T cell immunity targeting a broad-range
of non-classical Major Histocompatibility Class-II restricted Gag
epitopes (Hansen et al., 2011, 2013). Thus, although CMV may
not represent an ideal vector with respect to safety of use, the
strategy suggests that protection against persistent infection is
possible, provided the CD8+ T cell responses are sufficiently
robust and broad.
An alternative strategy that has gained considerable
momentum since its development is the use of 2-valent
mosaic antigens for vaccination (Barouch et al., 2010). The
2-valent mosaic antigens encompass native HIV Gag, Pol, and
Env sequences that are most conserved amongst the isolates of
clades B and C, and include as many CD4+ and CD8+ T cell
epitopes as possible. Vaccines encoding mosaic antigens are
capable of increasing the breadth of T cell responses to HIV
Gag from clades A, B, and C whilst not compromising humoral
immunity to Env from these clades (Barouch et al., 2010).
Furthermore, vaccination of uninfected macaques with Ad26,
Ad35, andMVAmosaic vaccines can elicit broad T cell responses
and protective polyfunctional antibody responses especially
when a liposome-based Env protein boost was used prior to
SIV challenge (Barouch et al., 2010, 2013, 2015). Recently, a
landmark therapeutic vaccination study exploited the Ad26 and
MVA mosaic vaccines in a regimen involving a toll like receptor
7 agonist to increase the breadth of T cell responses to SIV Gag,
Pol, and Env (Borducchi et al., 2016). In this study, the increased
breadth of SIV-specific T cell immunity rather than humoral
immunity correlated with partial protection and the regimen
also allowed 3/9 vaccinated macaques to completely control
SIVmac251 infection (Borducchi et al., 2016).
There may well also be a place for DNA vaccines especially
given their recent success in the clinic (Trimble et al., 2015). We
have recently shown that a novel cytolytic DNA vaccine which
encodes a mutant form of perforin in addition to the immunogen
is more immunogenic than a canonical DNA vaccine (Gargett
et al., 2014). We have also shown that a DNA vaccine
encoding Tat generated anti-Tat neutralizing antibodies (NAb)
that inhibited the function of Tat in an in vitro transactivation
assay (Tomusange et al., 2016b). As recent clinical trials reported
that a clade B Tat vaccine induced cross-clade anti-Tat NAb in
patients treated with ART, increased CD4+ T cell counts and
reduced the viral load (Ensoli et al., 2016; Loret et al., 2016), some
consideration should be given to combining a Gag/Pol/Env T cell
vaccine with a vaccine designed to elicit anti-Tat NAb. Overall,
the studies discussed above suggest that a vaccine vector designed
to elicit protective T cell immunity against HIV-1 will need to
encode as many conserved T cell immunogens of the virus as
possible.
FUTURE DIRECTIONS
Although there are no correlates of protection from HIV-1,
the induction of bNAb is considered to be the most desirable
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TABLE 1 | Future challenges for the development of a T cell-mediated vaccine.
Factor Importance and caveats
hCoice of immunogens â It is important to encode as many immunogens as possible to elicit T cell immunity as broadly as possible to highly conserved regions
of HIV-1 such as Gag and Pol.
â The caveat is that encoding variable regions of HIV-1 in a vaccine could drive immunodominant T cell responses to variable regions of
the virus. Expansion of CD4+ T cell responses that target variable regions of HIV-1 could also contribute to diminishing the efficacy of
a vaccine as they will be targets for infection.
Choice of vectors â Replication-competent vectors that can induce cross-presentation in antigen presenting cells or replication incompetent (defective)
vectors that can efficiently transduce antigen presenting cells are highly immunogenic. The chosen vector or a regimen involving several
vectors should also be able to elicit long-lasting mucosal T cell immunity or Trm cells in the gut and the genito-rectal mucosa.
â The caveat is that replication competent vectors can have cytopathic effects deemed unsafe for use in humans and the insert capacity
of a vector will also limit its ability to encode a broad range of immunogens. Vectors that can elicit Trm immunity in the vagina and the
gut against SIV or HIV need to be developed and evaluated for protective efficacy.
Heterotypic immunity â It is clear that a highly protective vaccination regimen will by necessity elicit heterotypic immunity (i.e., both T cell immunity and antibody
responses especially bNAb with potent neutralization capacity).
â A vaccination strategy that elicits high titres of potent bNAb continues to represent a significant challenge and it is not clear how to
develop a strategy that will elicit protective heterotypic immunity.
Translation â Repetitive low-dose SIV challenge of vaccinated macaques is accepted as the best method to evaluate efficacy of a potential HIV-1
vaccine to be trialed in humans.
â Thus far the most robust T cell vaccine tested in macaques elicited control of SIV infection in 50% of the vaccinated macaques
(Hansen et al., 2011). It is not clear whether this level of efficacy in macaques will translate to >50% efficacy in humans exposed to
HIV-1 as this is a requirement to license a vaccine for use in humans.
outcome for a HIV-1 vaccine, but a vaccine able to elicit such
antibodies has not yet been developed for humans. However,
many successful live attenuated virus vaccines (e.g., measles
and yellow fever virus) that elicit protective NAb also elicit T
cell immunity (Querec et al., 2006). HIV-1 employs multiple
strategies to evade NAb (Schiffner et al., 2013) and cell to
cell transmission is effective (Smith and Derdeyn, 2017). This
suggests that an effective HIV-1 NAb vaccine regimen should
also elicit CD8+ killer T cells, most likely against a broad
range of highly conserved viral antigens as discussed previously.
Thus, it is expected that a vaccine which will elicit heterotypic
immunity, viz. bNAb and CD8+ T cell immunity, targeting
conserved viral epitopes will be highly protective, but there are
significant challenges to achieve this goal (Table 1). Perhaps the
most urgent need with respect to a T cell-mediated vaccine
is to develop a vaccine with the ability to not only induce
systemic immune responses but also induce killer CD8+ T
cell immunity at genito-rectal mucosa and the gut. In this
regard, a vaccine with the capacity to elicit CD8+ Trm
cells in the genito-rectal mucosa and the gut represents a
plausible and a rational path for HIV-1 vaccine design in the
future.
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